Nic Ferrar holds a Masters of Mechanical Engineering degree from the University of Leeds. After graduating, Nic took a commercial role within the engineering software industry, which involved managing accounts in the automotive, aerospace and marine industries. Nic joined the patent profession in 2003, working for a London-based private practice. Since that time Nic has also gained experience in industry, at Rolls-Royce plc, where he both handled a patent prosecution caseload and advised the business on commercial Intellectual Property matters.
Nic qualified as a Patent Attorney in 2007 and has handled a wide variety of technical subject matter across a number of engineering disciplines, including aerospace, manufacturing, power and HVAC, as well as more general consumer goods. Nic also maintains a strong interest in IP protection for software-related innovations and has successfully prosecuted a number of patent applications in fields including design, analysis, control, diagnostics and health monitoring.
Nic is a Fellow of the Chartered Institute of Patent Attorneys and a member of the Institute’s Computer Technology Committee, and a Member of the European Patents Institute.
Nic was recommended in the Legal 500 UK 2017 PATMA: Patent Attorneys rankings.
"Adamson Jones IP Ltd is traditionally strong in the life sciences space, but is increasingly active in the fields of chemistry, mechanical engineering and advanced physics. The group was reshaped in 2017 when Steve Jones retired from partnership; he remains as a consultant, and the team is now led by Simon Cooper. Highlights included assisting a university spin-out with its patent filing, and advising Intersurgical on a freedom to operate opinion in respect of a number of new products including an innovation which is being developed in collaboration with a US doctor. Nicholas Ferrar is also recommended."
Legal 500 UK 2017
MD, UK engineering company
Katherine Wright, pharmaceutical patent attorney, comments on the risks of filing a patent application too early as recently highlighted in Regeneron v Kymab & Novo Nordisk.
All the latest news and events straight to your inbox. Fill in your details below.